Recent Updates
Recently added Catalysts

denileukin diftitox

Phase 2

Drug/Agent Toxicity by Tissue/Organ | Monoclonal antibody | Oncology |Ligand Pharmaceuticals Incorporated|Last Updated: May 30, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00006345Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell LymphomaPHASE2 COMPLETED - — — Nov 1, 1999Mar 1, 2004May 30, 201311 United States
Unlock Drug Trial Details
Study Design & Arms
PurposeSUPPORTIVE_CARE
Interventions
NameTypeDescription
denileukin diftitoxBIOLOGICAL -
dexamethasoneDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites11

DISEASE CHARACTERISTICS: Diagnosis of persistent or recurrent cutaneous T-cell lymphoma (CTCL) and suitable for denileukin diftitox therapy PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Albumin at lea...

Countries:United States
Unlock Eligibility Criteria